Arexvy and Abrysvo RSV vaccines prove cost-effective for U.S. seniors, slashing RSV illness risks. At $127 and $118 per dose, they offer substantial health savings, with potential budget impacts up to $6.78 billion in the first season, emphasizing their value in elder care.
https://medicine.yale.edu/news-article/new-rsv-vaccines-would-dramatically-reduce-illness-and-death-in-us-if-implemented-at-influenza-vaccination-levels/
https://redd.it/1ah667y
@r_sciencegeeks
https://medicine.yale.edu/news-article/new-rsv-vaccines-would-dramatically-reduce-illness-and-death-in-us-if-implemented-at-influenza-vaccination-levels/
https://redd.it/1ah667y
@r_sciencegeeks